Silverback Therapeutics Presents Interim Clinical Results in Tumor Study

  Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment –

– SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab –

– Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population –

– Management to host conference call today at 6:30 AM ET –

Conference Call and Webcast on Thursday, September 16, 2021, at 6:30 AM ET

Silverback’s management team will host a conference call today at 6:30 AM ET. A live webcast, including slides, can be accessed through the Events section of the Company’s website at https://ir.silverbacktx.com/news-events/events. An archived replay will be available shortly after the conclusion of the event.

https://www.businesswire.com/news/home/20210916005163/en/Silverback-Therapeutics-Presents-Interim-Clinical-Results-from-the-Ongoing-Phase-11b-Study-of-SBT6050-Alone-or-In-Combination-with-Pembrolizumab-in-Patients-with-Advanced-or-Metastatic-HER2-Expressing-Solid-Tumors